Company Description
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor.
The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
| Country | Cayman Islands |
| Founded | 2004 |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Yang Lu |
Contact Details
Address: Ugland House, PO Box 309 Grand Cayman, KY1-1104 Cayman Islands | |
| Phone | 848-230-7430 |
| Website | adlainortye.com |
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001944552 |
| CUSIP Number | 00704R109 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yang Lu | Co- Founder, Chief Executive Officer and Chairman |
| Dr. Kaiyang Tang | President |
| Dr. Xiaofeng Ye | Interim Chief Financial Officer and Vice President of Business Development and Commercialization Strategy |
| Dr. Ngai Chiu Tse M.D., Ph.D. | Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 20-F/A | Filing |
| Apr 30, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 29, 2025 | SCHEDULE 13G | Filing |
| Feb 27, 2025 | UPLOAD | Filing |
| Feb 14, 2025 | 20-F/A | Filing |
| Feb 14, 2025 | 6-K | Report of foreign issuer |
| Dec 31, 2024 | 6-K | Report of foreign issuer |
| Dec 18, 2024 | UPLOAD | Filing |